Aurinia Pharmaceuticals Inc. (Aurinia) is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs.
In January 2021, the company introduced LUPKYNIS (voclosporin), the first…
Analysis
Quality compounder
Aurinia Pharmaceuticals Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is attractive. The owner-earnings multiple stands at 6.4×; owner earnings: the cash an owner could take out each year.
Growth is moderate; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202683
97
2026
All-time high
97
Jun 2026
All-time low
83
Mar 2026
Average rank
90
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
76
—
—
—
Price/Earnings
3
—
—
—
Price/Book
45
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
53
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.